A functional substitution in the L-aromatic amino acid decarboxylase enzyme worsens somatic symptoms via a serotonergic pathway.
Adolescent
Adult
Amino Acid Substitution
/ genetics
Aromatic-L-Amino-Acid Decarboxylases
/ genetics
Case-Control Studies
Facial Pain
/ diagnosis
Female
Genetic Association Studies
/ methods
HEK293 Cells
Humans
Male
Medically Unexplained Symptoms
Middle Aged
Prospective Studies
Protein Structure, Secondary
Serotonin
/ genetics
Signal Transduction
/ genetics
Young Adult
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
28
02
2019
revised:
10
05
2019
accepted:
02
06
2019
pubmed:
10
6
2019
medline:
31
3
2020
entrez:
10
6
2019
Statut:
ppublish
Résumé
Heightened somatic symptoms are reported by a wide range of patients with chronic pain and have been associated with emotional distress and physical dysfunction. Despite their clinical significance, molecular mechanisms leading to their manifestation are not understood. We used an association study design based on a curated list of 3,295 single nucleotide polymorphisms mapped to 358 genes to test somatic symptoms reporting using the Pennebaker Inventory of Limbic Languidness questionnaire from a case-control cohort of orofacial pain (n = 1,607). A replication meta-analysis of 3 independent cohorts (n = 3,189) was followed by functional validation, including in silico molecular dynamics, in vitro enzyme assays, and measures of serotonin (5-HT) plasma concentration. An association with the T allele of rs11575542 coding for an arginine to glutamine substitution in the L-aromatic amino acid decarboxylase (AADC) enzyme was replicated in a meta-analysis of 3 independent cohorts. In a combined meta-analysis of all cohorts, this association reached p = 6.43 × 10 Using functional genomics approaches, we identified a polymorphism in the AADC enzyme that contributes to somatic symptoms through reduced levels of 5-HT. Our findings suggest a molecular mechanism underlying the pathophysiology of somatic symptoms and opens up new treatment options targeting the serotonergic system. ANN NEUROL 2019;86:168-180.
Substances chimiques
Serotonin
333DO1RDJY
Aromatic-L-Amino-Acid Decarboxylases
EC 4.1.1.28
DDC protein, human
EC 4.1.1.28
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-180Subventions
Organisme : Canada Excellence Research Chairs, Government of Canada
ID : CERC09
Pays : International
Organisme : CIHR
ID : G237818
Pays : Canada
Organisme : NIDCR NIH HHS
ID : U01DE017018
Pays : United States
Informations de copyright
© 2019 American Neurological Association.